# Phase 2 Lymphoma, B-Cell, Marginal Zone trials: 37 (2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 37 trials in phase 2 for Lymphoma, B-Cell, Marginal Zone that are recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Recruiting Phase 2 Lymphoma, B-Cell, Marginal Zone trials: 37 rows for $5, recruiting or not yet recruiting on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/recruiting/phase-2/lymphoma-b-cell-marginal-zone

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 37
- Recruiting or not yet: 37
- Read on: November 19, 2026

## Trials

The 25 newest of 37, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 18, 2026 | NCT07945353 | Orelabrutinib Plus 4 Gy Radiotherapy Versus 24 Gy Radiotherapy for Stage I/II MALT Lymphoma | Fudan University | Phase 2 | Not yet recruiting | MALT Lymphoma | 272 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07945353) |
| August 13, 2026 | NCT07763210 | Intrathecal Cytarabine and Hydrocortisone for the Early Treatment of ICANS in Patients Undergoing CAR T Therapy for Non Hodgkin Lymphoma | Vanderbilt-Ingram Cancer Center | Phase 2 | Recruiting | Non-hodgkin Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory Mantle Cell... | 59 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07763210) |
| July 20, 2026 | NCT07713459 | A Phase II Study to Evaluate the Efficacy of UF-KURE19 Cells in Patients With Relapsed or Refractory B Cell Non-Hodgkin Lymphomas | Kure Cells, INC | Phase 2 | Not yet recruiting | Lymphoma Nonhodgkin, Marginal Zone B Cell Lymphoma, Diffuse Large B Cell Lymphoma (DLBCL), Follicular B-cell... | 105 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07713459) |
| July 15, 2026 | NCT07705308 | A Prospective Study of Response-adapted Low-dose Radiotherapy Combined With Orelabrutinib for Localized Mucosa-associated Lymphoid Tissue... | Ruijin Hospital | Phase 2 | Not yet recruiting | Lymphoma of the Mucosa Associated Lymphoid Tissue (MALT) | 140 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07705308) |
| June 17, 2026 | NCT07654465 | Rituximab Maintenance Versus Observation After R2 Induction in Previously Untreated Marginal Zone Lymphoma | Sun Yat-sen University | Phase 2 | Not yet recruiting | Marginal Zone Lymphoma(MZL) | 144 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07654465) |
| June 10, 2026 | NCT07638722 | Testing Mosunetuzumab Alone, With Zanubrutinib, or With Polatuzumab Vedotin for Treating Marginal Zone Lymphoma That Came Back or Didn't... | SWOG Cancer Research Network | Phase 2 | Not yet recruiting | Recurrent Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Recurrent Nodal Marginal Zone... | 138 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07638722) |
| May 13, 2026 | NCT07583810 | Non-covalent BTK Inhibitor Nemtabrutinib in Combination With the CD20 Monoclonal Antibody Rituximab for the Treatment of Marginal Zone... | City of Hope Medical Center | Phase 2 | Recruiting | Conjunctival Mucosa-Associated Lymphoid Tissue Lymphoma, Gastric Mucosa-Associated Lymphoid Tissue Lymphoma, Marginal... | 35 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07583810) |
| April 28, 2026 | NCT07554898 | Ultra-low-dose Radiation Therapy Followed by Orelabrutinib as First-line Treatment for Stage Ⅰ-Ⅱ MALT Lymphoma | Zhejiang Cancer Hospital | Phase 2 | Recruiting | MALT Lymphoma | 60 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07554898) |
| March 4, 2026 | NCT07448324 | Orelabrutinib Combined With Rituximab ± Lenalidomide in Response-Adapted Stratified Therapy for Untreated MZL | The First Affiliated Hospital with Nanjing Medical University | Phase 2 | Recruiting | Marginal Zone Lymphoma(MZL) | 50 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07448324) |
| March 2, 2026 | NCT07441993 | Exploratory Study of Orelabrutinib in the Treatment of Early-stage Untreated MZL | Institute of Hematology & Blood Diseases Hospital, China | Phase 2 | Recruiting | Marginal Zone Lymphoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07441993) |
| January 28, 2026 | NCT07372365 | Orelabrutinib as Consolidation and Maintenance Therapy in Treatment-Naïve MZL. | The First Affiliated Hospital of Soochow University | Phase 2 | Recruiting | Marginal Zone Lymphoma (MZL) | 23 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07372365) |
| November 17, 2025 | NCT07231952 | A Study of Pirtobrutinib, Venetoclax, and Rituximab in People With Waldenström's Macroglobulinemia (WM)/Lymphoplasmacytic Lymphoma (LPL) | Memorial Sloan Kettering Cancer Center | Phase 2 | Recruiting | Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07231952) |
| October 6, 2025 | NCT07208981 | Orelabrutinib Combined With Zebetuzumab and Lenalidomide for the Treatment of Newly Diagnosed MZL | The First Affiliated Hospital with Nanjing Medical University | Phase 2 | Recruiting | Marginal Zone Lymphoma(MZL) | 169 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07208981) |
| August 27, 2025 | NCT07144657 | Prospective Study of Frontline Antibiotics Therapy in the Treatment of Early-stage HP-negative Gastric MALT Lymphoma | National Taiwan University Hospital | Phase 2 | Not yet recruiting | MALT Lymphoma of Stomach | 40 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07144657) |
| June 15, 2025 | NCT07022223 | Orelabrutinib Combined With Rituximab as First-line Systemic Treatment for Marginal Zone Lymphoma | Second Affiliated Hospital, Zhejiang University, School of Medicine | Phase 2 | Recruiting | Marginal Zone Lymphoma(MZL) | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07022223) |
| May 22, 2025 | NCT06986174 | A Phase 2 Study to Evaluate the Safety and Efficacy of Pacritinib in Relapsed or Refractory Waldenström Macroglobulinemia | Sponsor not shown (see the record) | Phase 2 | Recruiting | Waldenström Macroglobulinemia, Lymphoplasmacytic Lymphoma, B-Cell Lymphoproliferative Disorder, Indolent Lymphoma | 30 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06986174) |
| April 1, 2025 | NCT06905509 | Epcoritamab Plus Standard of Care Platinum-Based Chemotherapy and Autologous Hematopoietic Cell Transplant for the Treatment of Relapsed or... | University of California, Davis | Phase 2 | Recruiting | Recurrent Diffuse Large B-Cell Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent... | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06905509) |
| January 28, 2025 | NCT06796998 | Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) | Sponsor not shown (see the record) | Phase 2 | Recruiting | Marginal Zone Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Splenic Marginal Zone... | 25 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06796998) |
| January 27, 2025 | NCT06793189 | MZL-IPI Risk-adapted Targeted Therapy in Untreated MZL | Ruijin Hospital | Phase 2 | Recruiting | Marginal Zone Lymphoma(MZL) | 145 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06793189) |
| January 27, 2025 | NCT06792825 | HM2023-43:Ph 2 Trial of Tafasitamab With Lenalidomide+Rituximab in Treatment-naive FL and MZL | Masonic Cancer Center, University of Minnesota | Phase 2 | Recruiting | Follicular Lymphoma, Marginal Zone Lymphoma | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06792825) |
| November 22, 2024 | NCT06700798 | Orelabrutinib Combined With Rituximab Versus R-CVP in the Untreated MZL： A Randomized, Open Phase II Trial | Sponsor not shown (see the record) | Phase 2 | Recruiting | Marginal Zone Lymphoma(MZL) | 90 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06700798) |
| August 22, 2024 | NCT06566807 | Oxygen Study-Orelabrutinib Combined With Obinutuzumab(O2) for First-Line Treatment of Marginal Zone Lymphoma | Huai'an First People's Hospital | Phase 2 | Recruiting | Marginal Zone Lymphoma | 51 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06566807) |
| August 21, 2024 | NCT06563596 | Epco, Zanu, Ritux for R/R FL or MZL | Sponsor not shown (see the record) | Phase 2 | Recruiting | Follicular Lymphoma, Lymphoma, Non-Hodgkin Lymphoma, Relapsed Lymphoma, Refractory Lymphoma, Marginal Zone Lymphoma | 71 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06563596) |
| July 19, 2024 | NCT06510309 | Rituximab Plus Venetoclax in Front Line Marginal Zone Lymphoma | Sponsor not shown (see the record) | Phase 2 | Recruiting | Lymphoma, Marginal Zone Lymphoma, MZL | 33 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06510309) |
| July 17, 2024 | NCT06504940 | Optimize Study - Orelabrutinib Combined With BR/G in Untreated Marginal Zone Lymphoma (MZL) | First Affiliated Hospital of Zhejiang University | Phase 2 | Recruiting | Marginal Zone Lymphoma | 69 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06504940) |

## Sponsors with the most

| Sponsor | Trials |
| --- | --- |
| Masonic Cancer Center, University of Minnesota | 3 |
| Institute of Hematology & Blood Diseases Hospital, China | 2 |
| Ruijin Hospital | 2 |
| The First Affiliated Hospital with Nanjing Medical University | 2 |
| Peking Union Medical College Hospital | 1 |
| H. Lee Moffitt Cancer Center and Research Institute | 1 |
| Kure Cells, INC | 1 |
| Fred Hutchinson Cancer Center | 1 |
| University of Utah | 1 |
| City of Hope Medical Center | 1 |
| First Affiliated Hospital of Zhejiang University | 1 |
| Memorial Sloan Kettering Cancer Center | 1 |
| Fudan University | 1 |
| SWOG Cancer Research Network | 1 |
| University of Miami | 1 |
| Second Affiliated Hospital, Zhejiang University, School of Medicine | 1 |
| National Taiwan University Hospital | 1 |
| University of California, Davis | 1 |
| Vanderbilt-Ingram Cancer Center | 1 |
| The First Affiliated Hospital of Soochow University | 1 |
| Huai'an First People's Hospital | 1 |
| Sun Yat-sen University | 1 |
| Brown University | 1 |
| Emory University | 1 |
| Zhejiang Cancer Hospital | 1 |

## By country

| Country | Trials |
| --- | --- |
| United States | 20 |
| China | 15 |
| Taiwan | 1 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Contract law firms in the United States](https://specstream.ai/data/businesses/contract-law-firms/united-states)
- [Marketing agencies in the United States](https://specstream.ai/data/businesses/marketing-agencies/united-states)
- [Truck and industrial vehicle companies in the United States](https://specstream.ai/data/businesses/truck-and-industrial-vehicle-companies/united-states)
- [Demolition contractors in the United States](https://specstream.ai/data/businesses/demolition-contractors/united-states)
- [Metal plating companies in the United States](https://specstream.ai/data/businesses/metal-plating-companies/united-states)
- [Veterans hospitals in the United States](https://specstream.ai/data/businesses/veterans-hospitals/united-states)
